Plitidepsin

CHEMBL451930 Phase 4 अनुमोदित Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
1110.3 g/mol
LogP
5.7
Phase
4

Plitidepsin is a cyclic depsipeptide of marine origin derived from the tunicate Aplidium albicans that exerts anticancer activity by inhibiting protein synthesis through binding to eukaryotic elongation factor 1A2 (eEF1A2), disrupting the elongation phase of translation. It has demonstrated activity in multiple myeloma, T-cell lymphoma, and leukemia, and has also shown antiviral activity against SARS-CoV-2.

आणविक भार

1110.3000 g/mol

LogP

5.70

TPSA

285.00 Ų

लिपिंस्की RO5

अनुत्तीर्ण

चिकित्सीय क्षेत्र

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D संरचना

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC[C@H](C)[C@H]1NC(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H]2CCCN2C(=O)C(C)=O)[C@@H](C)OC(=O)[C@H](Cc2ccc(OC)cc2)N(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)C(=O)[C@H](C(C)C)OC(=O)C[C@@H]1O

InChI

InChI=1S/C57H87N7O15/c1-15-33(8)46-44(66)29-45(67)79-49(32(6)7)48(68)34(9)50(69)58-39(26-30(2)3)54(73)64-25-17-19-41(64)56(75)62(13)43(28-37-20-22-38(77-14)23-21-37)57(76)78-36(11)47(52(71)59-46)60-51(70)42(27-31(4)5)61(12)55(74)40-18-16-24-63(40)53(72)35(10)65/h20-23,30-34,36,39-44,46-47,49,66H,15-19,24-29H2,1-14H3,(H,58,69)(H,59,71)(H,60,70)/t33-,34-,36+,39-,40-,41-,42+,43-,44-,46+,47-,49-/m0/s1

Molecular Formula

C57H87N7O15

HBD / HBA

4 / 15

घूर्णनीय बंधन

15

भारी परमाणु

79

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

अक्सर पूछे जाने वाले प्रश्न

Plitidepsin is a cyclic depsipeptide of marine origin derived from the tunicate Aplidium albicans that exerts anticancer activity by inhibiting protein synthesis through binding to eukaryotic elongation factor 1A2 (eEF1A2), disrupting the elongation phase of translation. It has demonstrated activity in multiple myeloma, T-cell lymphoma, and leukemia, and has also shown antiviral activity against SARS-CoV-2.

Yes, Plitidepsin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL451930. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 9812534. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

चिकित्सा अस्वीकरण

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.